Andris S.
- Country
- Latvia
- Department
- N/A
Research Overview
- Efficacy and Safety of Inhaled Treprostinil Liposome in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)
- Phase 2 Study of REGN13335 Efficacy and Safety in Adults with Pulmonary Arterial Hypertension
- Efficacy and Safety of IKT-001 in Adults with WHO Group 1 Pulmonary Arterial Hypertension: An Adaptive, Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 442 of 786 partner sites.
Specializations
Pulmonary Vascular Disorders
The investigator specializes in treating complex pulmonary arterial hypertension (PAH) and related conditions, with particular focus on innovative therapeutic approaches including inhaled treatments.
- Advanced PAH Management
- Pulmonary Hypertension in Heart Failure
- Interstitial Lung Disease Complications
Works extensively with novel therapeutic agents targeting pulmonary vascular remodeling and pressure regulation.
Cardiovascular Medicine
Focuses on atherosclerotic cardiovascular disease (ASCVD) prevention and management, particularly in high-risk populations requiring innovative therapeutic interventions.
- Primary Cardiovascular Prevention
- Major Adverse Cardiovascular Events
- Cardiovascular Risk Management
Evaluates new approaches in cardiovascular risk reduction and disease prevention.
Specialty Areas
Demonstrates expertise in multiple therapeutic areas including inflammatory bowel disorders and neurological conditions.
- Crohn's Disease Treatment
- Chorioretinal Vascular Diseases
- Amyotrophic Lateral Sclerosis
Explores advanced therapeutic options for complex medical conditions requiring specialized intervention.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.